Cargando…

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals

The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terpos, Evangelos, Karalis, Vangelis, Ntanasis-Stathopoulos, Ioannis, Apostolakou, Filia, Gumeni, Sentiljana, Gavriatopoulou, Maria, Papadopoulos, Dimitris, Malandrakis, Panagiotis, Papanagnou, Eleni-Dimitra, Korompoki, Eleni, Kastritis, Efstathios, Papassotiriou, Ioannis, Trougakos, Ioannis P., Dimopoulos, Meletios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687721/ https://www.ncbi.nlm.nih.gov/pubmed/34938959 http://dx.doi.org/10.1097/HS9.0000000000000677

Ejemplares similares

Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study
por: Zirou, Christina, et al.
Publicado: (2023)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
por: Papadopoulos, Dimitris, et al.
Publicado: (2022)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
por: Terpos, Evangelos, et al.
Publicado: (2021)

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Organ-specific manifestations of COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Emerging treatment strategies for COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA
por: Terpos, E, et al.
Publicado: (2022)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

Boosting autophagy in anti-tumor proteasome inhibition-mediated cardiotoxicity
por: Papanagnou, Eleni-Dimitra, et al.
Publicado: (2023)

Autophagy activation can partially rescue proteasome dysfunction‐mediated cardiac toxicity
por: Papanagnou, Eleni‐Dimitra, et al.
Publicado: (2022)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Nrf2 activation induces mitophagy and reverses Parkin/Pink1 knock down-mediated neuronal and muscle degeneration phenotypes
por: Gumeni, Sentiljana, et al.
Publicado: (2021)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
por: Terpos, Evangelos, et al.
Publicado: (2020)

How I treat rituximab refractory patients with WM
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
por: Terpos, Evangelos, et al.
Publicado: (2018)

Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review
por: Korompoki, Eleni, et al.
Publicado: (2021)

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection
por: Malandrakis, Panagiotis, et al.
Publicado: (2020)

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients
por: Bergamaschi, Cristina, et al.
Publicado: (2021)

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent
por: Papanagnou, Eleni-Dimitra, et al.
Publicado: (2018)

Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019)

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_66cug2m086t1nur1khem5ur8v0